| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Agile Therapeutics Inc (NASDAQ: AGRX)
AGRX Technical Analysis
1
| As on N/A AGRX STOCK Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS. |
AGRXSTOCK Price
| Open | N/A | Change | Price | % |
| High | N/A | 1 Day | N/A | N/A |
| Low | N/A | 1 Week | N/A | N/A |
| Close | N/A | 1 Month | N/A | N/A |
| Volume | N/A | 1 Year | N/A | N/A |
| 52 Week High N/A | 52 Week Low N/A | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 131.76 | -1.10% |
| LMDX | 0.02 | 0.00% |
| BHAT | 0.06 | 0.00% |
| AKTS | 0.04 | 0.00% |
| TSLA | 396.36 | -1.72% |
| PONO | 1.72 | 2.38% |
| TELL | 1.00 | 0.00% |
| LCID | 2.96 | -1.66% |
| PLUG | 2.66 | -1.85% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AGRX Daily Charts |
AGRX Intraday Charts |
Whats New @ Bazaartrend |
AGRX Free Analysis |
|
|
AGRX Important Levels Intraday
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE |
AGRX Forecast January 2025
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
AGRX Weekly Forecast
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
AGRX Forecast2025
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
Agile Therapeutics Inc ( NASDAQ USA Symbol : AGRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AGRX Business Profile
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. Address: 101 Poor Farm Road, Princeton, NJ, United States, 08540
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service